Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Gross Profit came in at -$6.0 million in Q1 2026, up 15.05% YoY from -$5.2 million in Q1 2025, and down 128.3% on a QoQ basis from $21.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 6 years of Gross Profit data on file, last reported at -$6.0 million in Q1 2026.
- Quarterly Gross Profit rose 15.05% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 23.3% YoY) and the FY2025 annual result came in at $3.7 million, down 72.59% from the prior year.
- Gross Profit fell to -$6.0 million in Q1 2026, from $21.3 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $21.3 million in Q4 2025 to a low of -$9.5 million in Q3 2025.
- A 5-year average of $286294.1 and a median of -$344000.0 in 2023 frame the typical range for Gross Profit.
- The widest YoY moves for Gross Profit: up 4170.64% in 2024, down 916.63% in 2024.
- Tracing RXRX's Gross Profit over 5 years: stood at $2.8 million in 2022, then plunged by 64.39% to $1.0 million in 2023, then tumbled by 916.63% to -$8.2 million in 2024, then jumped by 357.8% to $21.3 million in 2025, then sank by 128.3% to -$6.0 million in 2026.
- The last three Gross Profit figures came in at -$6.0 million (Q1 2026), $21.3 million (Q4 2025), and -$9.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.82 Mn |
| Jun 30, 2026 | -3.82 Mn |
| Mar 31, 2026 | -6.02 Mn |
| Mar 31, 2026 | -6.02 Mn |
| Dec 31, 2025 | 21.26 Mn |
| Dec 31, 2025 | 21.26 Mn |
| Sep 30, 2025 | -9.51 Mn |
| Sep 30, 2025 | -9.51 Mn |
| Jun 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -938,000.00 |
| Mar 31, 2025 | -7.08 Mn |
| Mar 31, 2025 | -7.08 Mn |
| Dec 31, 2024 | -8.25 Mn |
| Dec 31, 2024 | -8.25 Mn |
| Sep 30, 2024 | 14.00 Mn |
| Sep 30, 2024 | 14.00 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.63 Mn |